INVIRASE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Invirase, and when can generic versions of Invirase launch?
Invirase is a drug marketed by Hoffmann La Roche and Hoffmann-la Roche and is included in two NDAs.
The generic ingredient in INVIRASE is saquinavir mesylate. There is one drug master file entry for this compound. Additional details are available on the saquinavir mesylate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for INVIRASE?
- What are the global sales for INVIRASE?
- What is Average Wholesale Price for INVIRASE?
Summary for INVIRASE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 57 |
| Clinical Trials: | 12 |
| Patent Applications: | 4,300 |
| Drug Prices: | Drug price information for INVIRASE |
| What excipients (inactive ingredients) are in INVIRASE? | INVIRASE excipients list |
| DailyMed Link: | INVIRASE at DailyMed |
Recent Clinical Trials for INVIRASE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Hoffmann-La Roche | Phase 1 |
| Hoffmann-La Roche | Phase 2 |
| National Institute of Mental Health (NIMH) | Phase 2/Phase 3 |
US Patents and Regulatory Information for INVIRASE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hoffmann La Roche | INVIRASE | saquinavir mesylate | CAPSULE;ORAL | 020628-001 | Dec 6, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hoffmann-la Roche | INVIRASE | saquinavir mesylate | TABLET;ORAL | 021785-001 | Dec 17, 2004 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for INVIRASE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hoffmann La Roche | INVIRASE | saquinavir mesylate | CAPSULE;ORAL | 020628-001 | Dec 6, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Hoffmann-la Roche | INVIRASE | saquinavir mesylate | TABLET;ORAL | 021785-001 | Dec 17, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for INVIRASE
See the table below for patents covering INVIRASE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Zimbabwe | 17490 | AMINO ACID DERIVATIVES | ⤷ Sign Up |
| China | 1138983 | ⤷ Sign Up | |
| Iceland | 1803 | ⤷ Sign Up | |
| Hungary | 908076 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for INVIRASE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0432695 | 32/1996 | Austria | ⤷ Sign Up | PRODUCT NAME: SAQUINAVIR UND SEINE SAEUREADDITIONSSALZE, INSBESONDERE SAQUINAVIRMESYLAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004 |
| 0432695 | 96C0044 | Belgium | ⤷ Sign Up | PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004 |
| 0432695 | C970013 | Netherlands | ⤷ Sign Up | PRODUCT NAME: SAQUINAVIR DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004 |
| 0034432 | 96C0048 | Belgium | ⤷ Sign Up | PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
